Isavuconazole and Nine Comparator Antifungal Susceptibility Profiles for Common and Uncommon Candida Species Collected in 2012: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values
Isavuconazole and Nine Comparator Antifungal Susceptibility Profiles for Common and Uncommon Candida Species Collected in 2012: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values
复制标题
DOI：
10.1007/s11046-014-9772-2
复制
发表时间：
2014-08-01
期刊：
影响因子：
5.5
通讯作者：
Pfaller, Michael A.
中科院分区：
文献类型：
--
作者：
Castanheira, Mariana;Messer, Shawn A.;Pfaller, Michael A.
使用参考肉汤微量稀释法评估了艾沙康唑和9种抗真菌对照药物对2012年全球调查中1，421种常见和不常见念珠菌的体外活性。使用CHROMagar、生物化学方法和ITS和/或28 S区域的测序鉴定分离株。念珠菌分别使用CLSI临床折点或流行病学截止值将抗真菌药物分类为敏感或耐药以及野生型（WT）或非WT。分离株包括来自21种不同念珠菌的1，421种微生物。在念珠菌属中，对所有10种测试的抗真菌剂的耐药性都很低（0.0- 7.9%）。除光滑念珠菌、克柔念珠菌和季也蒙念珠菌（模式MIC为0.5 A μ g/ml）外，绝大多数念珠菌种属均被千分之0.12 A μ g/ml艾沙康唑抑制（99.0%;范围94.3%[热带念珠菌]至100.0%[葡萄牙念珠菌和都柏林念珠菌]）。C.光叶C.克鲁斯念珠菌和近艾沙康唑的千分之一μ g/ml对季也蒙氏疟原虫的抑制率分别为89.7%、96.9%和92.8%。对艾沙康唑敏感性的降低在C.其中对于那些对氟康唑为SDD或对伏立康唑为WT的菌株，艾沙康唑的模式MIC为0.5 μ g/ml，而对于那些对氟康唑或伏立康唑为抗性或非WT的菌株，艾沙康唑的模式MIC分别为4 μ g/ml。总之，这些数据记录了艾沙康唑的活性，以及在一个大的、当代（2012年）、全球收集的分子特征念珠菌属中对可用抗真菌剂的耐药水平通常较低。
The in vitro activity of isavuconazole and nine antifungal comparator agents was assessed using reference broth microdilution methods against 1,421 common and uncommon species of Candida from a 2012 global survey. Isolates were identified using CHROMagar, biochemical methods and sequencing of ITS and/or 28S regions. Candida spp. were classified as either susceptible or resistant and as wild type (WT) or non-WT using CLSI clinical breakpoints or epidemiological cutoff values, respectively, for the antifungal agents. Isolates included 1,421 organisms from 21 different species of Candida. Among Candida spp., resistance to all 10 tested antifungal agents was low (0.0-7.9 %). The vast majority of each species of Candida, with the exception of Candida glabrata, Candida krusei, and Candida guilliermondii (modal MICs of 0.5 A mu g/ml), were inhibited by a parts per thousand currency sign0.12 A mu g/ml of isavuconazole (99.0 %; range 94.3 % [Candida tropicalis] to 100.0 % [Candida lusitaniae and Candida dubliniensis]). C. glabrata, C. krusei, and C. guilliermondii were largely inhibited by a parts per thousand currency sign1 A mu g/ml of isavuconazole (89.7, 96.9 and 92.8 %, respectively). Decreased susceptibility to isavuconazole was most prominent with C. glabrata where the modal MIC for isavuconazole was 0.5 A mu g/ml for those strains that were SDD to fluconazole or WT to voriconazole, and was 4 A mu g/ml for those that were either resistant or non-WT to fluconazole or voriconazole, respectively. In conclusion, these data document the activity of isavuconazole and generally the low resistance levels to the available antifungal agents in a large, contemporary (2012), global collection of molecularly characterized species of Candida.